Impact of medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska

Health Services Research

Volumn 43, Issue 1 P2, 2008, Pages 435-450

  Siracuse, Mark V ^a   Vuchetich, Phillip J ^b  

^a CREIGHTON UNIVERSITY   (United States)

^b ALEGENT HEALTH   (United States)

Author keywords

COX 2 inhibitors; Drug policy; Medicaid; Pharmacy costs; Prior authorization

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; COST; COST CONTROL; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; MEDICAID; PHARMACY; POLICY; PRESCRIPTION; RECIPIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DRUG COSTS; DRUG UTILIZATION; HEALTH POLICY; HUMANS; MEDICAID; NEBRASKA; RETROSPECTIVE STUDIES;

EID: 38149087431     PISSN: 00179124     EISSN: 14756773     Source Type: Journal    
DOI: 10.1111/j.1475-6773.2007.00766.x     Document Type: Article

References (21)

1. Altman, S. H. C. Parks-Thomas. 2002 Controlling Spending for Prescription Drugs New England Journal of Medicine 346 (11) : 855 6.
2. Bombardier, C., L. Laine, A. Reicin, D. Shapiro, R. Burgos Vargas, B. Davis, R. Day, M. B. Ferraz, C. J. Hawkey, M. C. Hochberg, T. K. Kvien, T. J., Schnitzer VIGOR-Study-Group. 2000 Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. VIGOR-Study-Group New England Journal of Medicine 343 (21) : 1520,8, 2 p following 1528.
3. Centers for Medicare and Medicaid Services. 2004. "MSIS State Summary FY 2001" [accessed on June 12, 2006]. Available at
4. Centers for Medicare and Medicaid Services. 2005. "MSIS State Summary FY 2002" [accessed on June 12, 2006]. Available at
5. Centers for Medicare and Medicaid Services. 2006. "MSIS State Summary FY2003" [accessed on June 12, 2006]. Available at
6. Curtiss, F. R. 2006 Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam Journal of Managed Care Pharmacy 12 (3) : 265 8.
7. Fischer, M. A., S. Schneeweiss, J. Avorn D. H. Solomon. 2004 Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors New England Journal of Medicine 351 (21) : 2187 94.
8. Gleason, P. P., C. Williams, S. Hardy, S. C. Hartwig D. Lassen. 2005 Medical and Pharmacy Expenditures after Implementation of a Cyclooxygenase-2 Inhibitor Prior Authorization Program Pharmacotherapy 25 (7) : 924 34.
9. Hamel, M. B. A. M. Epstein. 2004 Prior-Authorization Programs for Controlling Drug Spending New England Journal of Medicine 351 (21) : 2156 8.
10. Hartung, D. M., D. R. Touchette, K. L. Ketchum, D. G. Haxby B. W. Goldberg. 2004 Effects of a Prior-Authorization Policy for Celecoxib on Medical Service and Prescription Drug Use in a Managed Care Medicaid Population Clinical Therapeutics 26 (9) : 1518 32.
11. Juni, P., A. W. Rutjes P. A. Dieppe. 2002 Are Selective COX 2 Inhibitors Superior to Traditional Non Steroidal Anti-Inflammatory Drugs? British Medical Journal Clinical Research Edition 324 (7349) : 1287 8.
12. Kaiser Family Foundation. 2004. "Prescription Drug Trends" [accessed on April 15, 2006]. Available at
13. Kaiser Family Foundation. 2005. "Prescription Drug Trends, November 2005" [accessed on June 1, 2006]. Available at
14. Momani, A. A., S. S. Madhavan D. P. Nau. 2002 Impact of NSAIDs Prior Authorization Policy on Patients' QoL Annals of Pharmacotherapy 36 (11) : 1686 91.
15. Phillips, C. R. L. N. Larson. 1997 Evaluating the Operational Performance and Financial Effects of a Drug Prior Authorization Program Journal of Managed Care Pharmacy 3 (6) : 699 706.
16. Rosenthal, M. B., E. R. Berndt, J. M. Donohue, R. G. Frank A. M. Epstein. 2002 Promotion of Prescription Drugs to Consumers New England Journal of Medicine 346 (7) : 498 505.
17. Shaw, E., J. Stacy, M. D. Arledge D. Howell Smith. 2003 Pharmacoeconomic Modeling of Prior-authorization Intervention for COX-2 Specific Inhibitors in a 3-Tier Copay Plan Journal of Managed Care Pharmacy 9 (4) : 327 34.
18. Smalley, W. E., M. R. Griffin, R. L. Fought, L. Sullivan W. A. Ray. 1995 Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Antiinflammatory Drugs by Medicaid Patients New England Journal of Medicine 332 (24 1612 17.
19. Smith, C., C. Cowan, S. Heffler A. Catlin. 2006 National Health Spending in 2004: Recent Slowdown Led by Prescription Drug Spending Health Affairs 25 (1) : 186 96.
20. State of Nebraska Department of Health and Human Services. 2005. "COX-2 NSAIDs: Nebraska Medicaid Prior Authorization Process" [accessed on June 12, 2006]. Available at :
21. Stockl, K., L. Cyprien E. Y. Chang. 2005 Gastrointestinal Bleeding Rates among Managed Care Patients Newly Started on COX-2 Inhibitors or Nonselective NSAIDs Journal of Managed Care Pharmacy 11 (7) : 550 8.